2021 IMPACT OF COVID-19 AND IBD IN CANADA REPORT
2017
Impact of IBD Report
Posters and Abstracts
2022
Kuenzig E, Mason J, Bernstein CN, Gomes T, Juurlink D, Kaplan GG, Peña-Sanchez J, Targownik LE, Vigod S, Begum J, Nugent Z, Benchimol EI. Chronic opioid therapy is associated with increased health services utilization and direct healthcare costs: a population-based study. J Can Assoc Gastroenterol 2022; 5(Supplement_1): 39-41.
Presented at Canadian Digestive Diseases Week 2022 (Virtual).
Kuenzig E, Mason J, Bernstein CN, Gomes T, Juurlink D, Kaplan GG, Peña-Sanchez J, Targownik LE, Vigod S, Begum J, Nugent Z, Benchimol EI. Opioid use is declining among people with inflammatory bowel disease: a population-based study. J Can Assoc Gastroenterol 2022; 5(Supplement_1): 35-37.
Presented at Canadian Digestive Diseases Week 2022 (Virtual).
El Matary W, Witt J, Bernstein CN, Jacobson K, Mack DR, Otley A, Walters T, Huynh HQ, deBruyn J, Griffiths A, Benchimol EI. Estimating indirect and out-of-pocket disease-associated costs in pediatric inflammatory bowel disease: a nation-wide cross-sectional analysis. J Can Assoc Gastroenterol 2022; 5(Supplement_1): 26-27.
Presented at Canadian Digestive Diseases Week 2022 (Virtual).
El Matary W, Witt J, Bernstein C, Jacobson K, Mack D, Otley A, Walters T, Huynh H, deBruyn J, Griffiths A, Benchimol E. Estimating indirect and out-of-pocket disease-associated costs in paediatric Inflammatory Bowel Disease: a nation-wide cross-sectional analysis. J Crohns Colitis 2022; 16(Supplement_1): i554.
Presented at the 17th Congress of the European Crohn’s and Colitis Organization (Virtual).
2020
Targownik LE, Tennakoon A, Bernstein CN, Singh H, Benchimol EI, Kaplan GG, Coward S, Kuenzig E, Murthy S. Earlier anti-TNF initiation promotes lower subsequent direct healthcare utilization in persons with inflammatory bowel disease in the real world. Gastroenterology. 2020;158(6, Supplement 1):S96-7.
Hitz L, Tennakoon A, Benchimol EI, Bernstein CN, Coward S, Kaplan GG, Kuenzig E, Murthy S, Silverberg MS, Singh H, Targownik LE. The long-term corticosteroid sparing effect of anti-TNF therapy in a real world Crohn’s disease cohort. Gastroenterology. 2020;158(6, Supplement 1):S655.
Kuenzig E, Singh H, Bitton A, Kaplan GG, Carroll MW, Otley A, Stukel TA, Spruin S, Nugent Z, Tanyingoh D, Cui Y, Filliter C, Coward S, Griffiths A, Mack D, Jacobson K, Nguyen GC, Targownik L, El-Matary W, Benchimol EI. Pediatric-onset inflammatory bowel disease increases the risk of venous thromboembolism: A CanGIEC population-based study. J Can Assoc Gastoenterol 2020; 3(Supplement 1): 31-33.
Presented as a poster (by student) at Canadian Digestive Diseases Week, Montreal, QC (March 1, 2020)
Dheri A, Kuenzig E, Mack D, Murthy S, Kaplan GG, Benchimol EI. Decreasing hospitalizations and surgeries in children with inflammatory bowel disease: a population-based study. J Can Assoc Gastoenterol 2020; 3(Supplement 1): 69-71.
Presented as a poster (by student) at Canadian Digestive Diseases Week, Montreal, QC (February 29, 2020)
Coward S, Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Jelinski S, Jones J, Kuenzig E, Leddin D, Murthy S, Nguyen GC, Otley A, Rezaie A, Peña-Sanchez J, Singh H, Stach J, Targownik L, Windsor JW, Kaplan GG. Hospitalization in inflammatory bowel disease: A population-based comparison of definitions. J Can Assoc Gastoenterol 2020; 3(Supplement 1): 76-78.
Kuenzig E, Singh H, Bitton A, Kaplan GG, Carroll MW, Otley A, Stukel TA, Spruin S, Griffiths A, Mack D, Jacobson K, Nguyen GC, Targownik L, El-Matary W, Nasiri S, Benchimol EI. Variation in the care of children with inflammatory bowel disease: A CanGIEC population-based study. J Can Assoc Gastoenterol 2020; 3(Supplement 1): 78-79.
Presented as a poster (by student) at Canadian Digestive Diseases Week, Montreal, QC (March 1, 2020)
2019
Coward S, Benchimol E, Clement F, Hazlewood G, Kuenzig E, McBrien K, Deardon R, Panaccione R, Seow C, Windsor JW, Kaplan G. The incidence of inflammatory bowel disease: analyzing historical trends to predict the future. Inflamm Bowel Dis 2019; 25(Suppl 1): S50-S51.
Targownik LE, Witt J, Bernstein CN, Singh H, Aviña-Zubieta A, Benchimol EI, Coward S, Jones J, Kaplan GG, Nguyen GC, Peña-Sanchez J, Shaffer S, Tennakoon A. Longitudinal changes in the direct cost of IBD care in the biologic era. J Can Assoc Gastroenterol 2019;2(Suppl 2):1-3.
Coward S, Benchimol EI, Clement F, Hazlewood G, Kuenzig E, McBrien K, Deardon R, Panaccione R, Seow C, Windsor JW, Kaplan GG. The evolving incidence of inflammatory bowel disease: What will the future hold? J Can Assoc Gastroenterol 2019;2(Suppl 2): 56-68.
*Poster of distinction at Canadian Digestive Diseases Week 2019
Targownik LE, Witt JC, Tennakoon A, Bernstein CN, Singh H, Aviña-Zubieta A, Kaplan G, Coward S, Peña-Sanchez JN, Nguyen GC, Kuenzig E, Murthy SK, Benchimol EI. Longitudinal changes in the direct costs of IBD care in the biologic era. Gastroenterol 2019;156(6 Suppl 1): S-24.
Coward S, Benchimol EI, Clement F, Hazlewood G, Kuenzig E, McBrien K, Deardon R, Panaccione R, Seow CH, Windsor JW, Kaplan G. The incidence of inflammatory bowel disease: Analyzing historical trends to predict the future. Gastroenterol 2019;156(6 Suppl 1): S-403-S-404.
Targownik LE, Benchimol EI, Bernstein CN, Singh H, Kaplan G, Lix L, Tennakoon A, Nguyen GC, Aviña-Zubieta A, Coward S, Panaccione R, Seow CH, Peña-Sanchez JN, Jones JL, Murthy SK, Kuenzig E. Rates of treatment ineffectiveness after initiating anti-TNF therapy: Results of a pooled population based interprovincial analysis Gastroenterol 2019;156(6 Suppl 1): S-610.
Targownik LE, Bernstein CN, Tennakoon A, Kaplan G, Singh H, Murthy SK, Nguyen GC, Benchimol EI. The rates of anti-TNF dose augmentation in people with inflammatory bowel disease: Real-world experience from a population-based cohort. Gastroenterol 2019;156(6 Suppl 1): S-880.
Laura E. Targownik, Aruni Tennakoon, Antonio Avina-Zubieta, Gilaad Kaplan, Juan-Nicolas Pena-Sanchez, Harminder Singh, Charles N. Bernstein. What is the Natural History of Persons with Adverse IBD Related Outcomes While Using Anti-TNF Based Therapy. Gastroenterology, Vol. 156, Issue 6, S-261
Laura E. Targownik, Casandra Dolovich, Aruni Tennakoon, Zoann Nugent, James Bolton, Jitender Sareen, Ruth Ann Marrie, Harminder Singh, Charles N. Bernstein. Mood and Anxiety Disorders and Persistance with Anti-TNF Therapy in IBD. Gastroenterology, Vol. 156, Issue 6, S-880
Wael El-Matary, Stella Leung, Aruni Tennakoon, Eric I. Benchimol, Charles N. Bernstein, Laura E. Targownik. Trends of Utilization of Tumor Necrosis Factor Antagonists in Children with Inflammatory Bowel Disease. Gastroenterology, Vol. 156, Issue 6, S-614
2018
Presented at Digestive Disease Week 2018, Washington, DC:
Benchimol EI, Bernstein CN, Nguyen GC, Targownik LE, Guttmann A, Jones JL, Potter B, Kuenzig E, Catley C, Nugent Z, Tanyingoh D, Mojaverian N, Underwood FE, Kaplan G. Disparities in the care of rural and urban Canadians with inflammatory bowel disease: A population-based study from the Canadian Gastro-Intestinal Epidemiology Consortium. Gastroenterol 2018; 154(6 Suppl 1): S-601.
*Poster of distinction
Targownik LE, Dolovich C, Shafer LA, Bernstein CN, Singh H, Rosenfeld G, Leung Y, Seow CH, Metcalfe A, Pena-Sanchez JN, Jones JL, Nguyen GC, Baxter NN, Moore S. Benchimol EI. The effects of disease severity and surgical status on fertility rates in Crohn’s disease and ulcerative colitis. Gastroenterol 2018; 154(6 Suppl 1): S-602.
Targownik LE, Dolovich C, Shafer LA, Bernstein CN, Singh H, Rosenfeld G, Leung Y, Seow CH, Metcalfe A, Pena-Sanchez JN, Jones JL, Nguyen GC, Benchimol EI. Rates of prematurity and low birth weight babies among a North American Cohort of women with IBD. Gastroenterol 2018; 154(6 Suppl 1): S-604.
Targownik LE, Tennakoon A, Bernstein CN, Singh H, Lix L, Kaplan G, Pena-Sanchez JN, Murthy SK, Nguyen GC, Jones JL, Benchimol EI. Continuing use of combination therapy is superior to anti-TNF monotherapy beyond 12 months: A population based study. Gastroenterol 2018; 154(6 Suppl 1): S-828.
*Poster of distinction
Targownik LE, Leung S, Singh H, Lix L, Kaplan G, Pena-Sanchez JN, Jones JL, Murthy SK, Nguyen GC, Benchimol EI, Bernstein CN. Is there still a role for immunomodulator monotherapy in IBD. Gastroenterol 2018; 154(6 Suppl 1): S-848.
Coward S, Clement F, Benchimol EI, Bernstein CN, Bitton A, Carroll M, Hazlewood G, Jelinski S, Jones JL, Kuenzig E, Leddin D, McBrien K, Murthy SK, Nguyen GC, Otley A, Rezaie A, Pena-Sanchez JN, Singh H, Targownik LE, Kaplan G. Analyzing the rising prevalence of IBD: Predicting the prevalence in 2030 by age group. Gastroenterol 2018; 154(6 Suppl 1): S-992-S-993.
*Poster of distinction
Presented at Canadian Digestive Diseases Week 2018, Toronto, ON:
Coward S, Clement F, Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Hazlewood G, Jelinski S, Jones J, Kuenzig E, Leddin D, McBrien K, Murthy S, Nguyen GC, Otley A, Rezaie A, Pena-Sanchez J, Singh H, Targownik L, Kaplan GG. The rising prevalence of inflammatory bowel disease in Canada: Analyzing the past to predict the future. J Can Assoc Gastroenterol 2018; 1(Suppl 2): 47-48.
*Poster of distinction
Benchimol EI, Bernstein CN, Nguyen GC, Targownik L, Guttmann A, Jones J, Potter BK, Kuenzig E, Catley CA, Tanyingoh D, Nugent Z, Mojaverian N, Underwood F, Kaplan GG. Disparities in the care of rural and urban Canadians with inflammatory bowel disease: A population-based study. J Can Assoc Gastroenterol 2018; 1(Suppl 2): 51-52.
*Poster of distinction
Targownik LE, Benchimol EI, Seow C, Nguyen GC, Pena-Sanchez J, Jones J, Metcalfe A, Dolovich C, Bernstein CN, Singh H. Canadian women with IBD are more likely to give birth to low birth weight infants. J Can Assoc Gastroenterol 2018; 1(Suppl 2): 159-160.
2017
Targownik LE, Bernstein CN, Singh H, Nugent Z, Tennakoon A, Leung S, Lix L, Benchimol EI, Nguyen GC, Kaplan G, Pena-Sanchez J-N, Jones JL, Jacobson K, Murthy SK, Bitton A. Concomitant immunomodulator is associated with a decreased risk of anti-TNF discontinuation and substitution: A population-based study. Gastroenterol 2017; 152(5 Suppl 1): S970.
2016
Benchimol E, Bernstein C, Bitton A, Carroll M, El-Matary W, Otley A, Singh H, Nguyen G, Griffiths A, Mack D, Mojaverian N, Vutcovici M, Cui Y, Nugent Z, Tanyingoh D, Kaplan G. Trends in incidence of pediatric inflammatory bowel disease in Canada: Population-based estimates from the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC). Can J Gastroenterol Hepatol 2016;2016:4792898.
Presented as an oral abstract at Canadian Digestive Diseases Week, Montreal, QC (February 26, 2016).
Carroll MW, Kaplan GG, Bernstein CN, Bitton A, Singh H, Otley AR, Vutcovici M, El-Matary W, Nguyen GC, Griffiths AM, Mack DR, Jacobson K, Mojaverian N, Tanyingoh D, Cui Y, Nugent Z, Coulombe J, Targownik L, Jones J, Leddin D, Benchimol E. Trends in epidemiology of pediatric inflammatory bowel disease in Canada: Distributed network analysis of multiple population-based provincial health administrative databases – the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC). J PediatrGastroenterolNutr2016; 63(Suppl 2): S275-S276.
Presented as an oral abstract at World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Montreal QC (October 7, 2016).
2015
Benchimol EI, Kaplan G, Nguyen GC, Jones JL, Guttmann A, Potter BK, Catley CA, Underwood FE, Nugent Z, Targownik L, Leddin D, Otley AR, Bernstein CN. The influence of rural/urban environment on the risk of inflammatory bowel disease in Canada: A population-based and birth cohort study from the Canadian Gastro-Intestinal Epidemiology Consortium (CanGIEC). Gastroenterol 2015; 148(4 Supplement 1): S-3.Presented as an oral abstract: Digestive Disease Week, Washington, DC (May 16, 2015).
Targownik LE, Nguyen GC, Metcalfe A, Benchimol EI, Jones JL, Kaplan GG, Rosenfeld G, Lam MC, Nugent Z, Leung Y, Seow CH. Pregnancy And Birth Rates Are Decreased Among Women With IBD: Results Of A Canadian Population-Based Cohort Study Gastroenterol2015; 148(4 Supplement 1): S-470.